DK2066339T3 - Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner - Google Patents
Sammensætninger og fremgangsmåder til forstærkning af immunreaktionerInfo
- Publication number
- DK2066339T3 DK2066339T3 DK07842706.9T DK07842706T DK2066339T3 DK 2066339 T3 DK2066339 T3 DK 2066339T3 DK 07842706 T DK07842706 T DK 07842706T DK 2066339 T3 DK2066339 T3 DK 2066339T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- methods
- immune reactions
- boosting immune
- boosting
- Prior art date
Links
- 230000008105 immune reaction Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82598306P | 2006-09-18 | 2006-09-18 | |
PCT/US2007/078785 WO2008036675A2 (en) | 2006-09-18 | 2007-09-18 | Compositions and methods of enhancing immune responses |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2066339T3 true DK2066339T3 (da) | 2014-11-03 |
Family
ID=39201208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07842706.9T DK2066339T3 (da) | 2006-09-18 | 2007-09-18 | Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner |
Country Status (10)
Country | Link |
---|---|
US (3) | US8604178B2 (da) |
EP (3) | EP2066339B1 (da) |
KR (1) | KR101460551B1 (da) |
CN (1) | CN101522210B (da) |
DK (1) | DK2066339T3 (da) |
ES (1) | ES2520026T3 (da) |
MY (2) | MY183797A (da) |
PL (1) | PL2066339T3 (da) |
PT (1) | PT2066339E (da) |
WO (1) | WO2008036675A2 (da) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1229045A1 (en) * | 2001-02-01 | 2002-08-07 | Institut Curie | Universal carrier for targeting molecules to Gb3 receptor expressing cells |
KR101460551B1 (ko) * | 2006-09-18 | 2014-11-18 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역 반응을 향상시키는 조성물 및 방법 |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
US9125854B2 (en) * | 2007-10-30 | 2015-09-08 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
CA3051748C (en) | 2007-11-01 | 2022-07-12 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
EP2464383A4 (en) | 2009-08-14 | 2013-02-13 | Theraclone Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF FLU |
PL2525817T3 (pl) | 2010-01-21 | 2018-01-31 | Univ Arkansas | Wektory szczepionkowe i sposoby wzmacniania odpowiedzi immunologicznych |
UA113496C2 (xx) | 2010-06-09 | 2017-02-10 | Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter | |
US8900585B2 (en) | 2010-10-20 | 2014-12-02 | New York Blood Center, Inc. | Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection |
KR101360112B1 (ko) | 2011-05-30 | 2014-02-06 | 건국대학교 산학협력단 | 공기전파가 가능한 신규한 h9n2형 저병원성 조류인플루엔자 바이러스 균주 및 그로부터 유래된 백신 |
DE102012006546B4 (de) | 2012-04-02 | 2018-02-08 | Trw Automotive Electronics & Components Gmbh | Kapazitiver Sensor, Verfahren zum Auslesen eines kapazitiven Sensorfeldes und Verfahren zur Herstellung eines kapazitiven Sensorfeldes |
WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
JP6532407B2 (ja) | 2013-02-14 | 2019-06-19 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法 |
MX2015012855A (es) | 2013-03-15 | 2016-07-21 | Univ Arkansas | Composiciones y metodos para aumentar la respuesta inmune contra patogenos entericos. |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
TW202224701A (zh) | 2016-05-03 | 2022-07-01 | 阿肯色州大學董事會 | 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN108373507A (zh) * | 2018-01-18 | 2018-08-07 | 复旦大学 | 一种重组亚单位禽流感疫苗Sef4M2e |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
EP3996731A4 (en) * | 2019-07-12 | 2023-07-12 | Op-T Llc | PEPTIDES AND METHODS OF TREATING DISEASES |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
WO2023076820A1 (en) * | 2021-10-26 | 2023-05-04 | Navicure Biopharmaceuticals Limited | Immunogenic fusion proteins against coronavirus |
CN114854654B (zh) * | 2022-04-06 | 2023-12-15 | 青岛易邦生物工程有限公司 | 一种肠炎沙门氏菌活疫苗 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3415145B2 (ja) * | 1991-03-05 | 2003-06-09 | ザ ウエルカム ファウンデーション リミテッド | 弱毒化細菌における組換えタンパク質の発現 |
US5981724A (en) * | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
DE69233402T3 (de) | 1991-10-25 | 2009-06-25 | Immunex Corp., Seattle | Neue cytokine |
US7405270B2 (en) * | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
DE69322092T2 (de) * | 1992-09-04 | 1999-07-15 | Univ Saskatchewan | Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien |
AU1059095A (en) | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
NZ305083A (en) | 1995-03-01 | 1999-06-29 | Immunex Corp | Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response |
DE69631331T2 (de) | 1995-06-07 | 2004-11-18 | Immunex Corp., Seattle | Cd40l mutein |
US6479258B1 (en) * | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US6713279B1 (en) * | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
US6306387B1 (en) * | 1997-05-29 | 2001-10-23 | The Research Foundation Of State University Of New York | Antigen delivery system |
US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
AU2004199A (en) | 1997-12-19 | 1999-07-12 | Immunex Corporation | Method for reducing susceptibility to hiv infection |
GB9806449D0 (en) * | 1998-03-25 | 1998-05-27 | Peptide Therapeutics Ltd | Attenuated bacteria useful in vaccines |
US6190669B1 (en) * | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
ES2356863T3 (es) * | 1998-09-04 | 2011-04-13 | Emergent Product Development Uk Limited | Mutantes de spi2 de salmonella atenuada como portadores de antígenos. |
US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
EP1067194A1 (en) | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
IL144952A0 (en) | 1999-04-16 | 2002-06-30 | Hoffmann La Roche | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
WO2001026608A2 (en) * | 1999-10-14 | 2001-04-19 | Ledbetter Jeffrey A | Dna vaccines encoding antigen linked to a domain that binds cd40 |
ES2222152T3 (es) * | 1999-12-28 | 2005-02-01 | Akzo Nobel N.V. | Vacuna con las salmonellas que no inducen anticuerpos que reaccionan con la flagelina o los flagelos. |
WO2001056602A2 (en) | 2000-02-02 | 2001-08-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd40 ligand adjuvant for respiratory syncytial virus |
WO2001070247A2 (en) * | 2000-03-17 | 2001-09-27 | Pharmacia & Upjohn Company | Salmonella vaccine materials and methods |
GB0015426D0 (en) * | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
GB0025132D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Method |
AU2002221780A1 (en) | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
WO2002092773A2 (en) * | 2001-05-15 | 2002-11-21 | Ortho-Mcneil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
RU2004103468A (ru) | 2001-07-06 | 2005-04-20 | Абик Байолоджикал Лэборетериз Тева Лтд. (Il) | Нуклеиновые кислоты, кодирующие рекомбинантный 250 к-да-антиген спорозоитов/мерозоитов eimeria maxima, и их применения |
ZA200400479B (en) | 2001-07-06 | 2006-05-31 | Abic Biolog Lab Teva | Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use |
US6923958B2 (en) * | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
WO2003096812A1 (en) * | 2002-04-15 | 2003-11-27 | Washington University | Regulated attenuation of live vaccines to enhance cross protective immunogenicity |
US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
NZ540067A (en) | 2002-11-20 | 2007-05-31 | Critical Therapeutics Inc | A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB |
US20050196583A1 (en) | 2002-12-03 | 2005-09-08 | Provost George A. | Embossing loop materials |
US20050181994A1 (en) * | 2003-01-06 | 2005-08-18 | Xencor, Inc. | Novel variants of CD40L protein |
US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
EP1673389A2 (en) | 2003-10-10 | 2006-06-28 | Xencor Inc. | Novel variants of cd40l protein |
US8828957B2 (en) * | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
CA2548347A1 (en) | 2003-12-11 | 2005-06-30 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
WO2005113598A2 (en) | 2004-05-21 | 2005-12-01 | Xencor, Inc. | Tnf super family members with altered immunogenicity |
EP1814576A2 (en) | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
AU2005294150B2 (en) | 2004-10-07 | 2011-06-16 | Coimmune, Inc. | Mature dendritic cell compositions and methods for culturing same |
US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
NZ556004A (en) * | 2004-12-21 | 2010-05-28 | Vaxinnate Corp | Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein |
WO2006105972A1 (en) | 2005-04-07 | 2006-10-12 | Universite Libre De Bruxelles | Transgenic organism expressing cd40l and uses thereof |
US20060286074A1 (en) * | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
ATE469657T1 (de) | 2005-10-07 | 2010-06-15 | Proyecto Biomedicina Cima Sl | Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c |
US9533036B2 (en) * | 2005-11-07 | 2017-01-03 | Microvax, Llc | Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein |
WO2007054658A1 (en) | 2005-11-14 | 2007-05-18 | King's College London | Control of immune responses |
WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
KR101460551B1 (ko) * | 2006-09-18 | 2014-11-18 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역 반응을 향상시키는 조성물 및 방법 |
WO2008109825A2 (en) | 2007-03-08 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Inducing immune-mediated tumor cell death |
US9125854B2 (en) * | 2007-10-30 | 2015-09-08 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
CA3051748C (en) * | 2007-11-01 | 2022-07-12 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
BR112014011443A2 (pt) | 2011-11-11 | 2017-05-02 | Nutrition Physiology Company Llc | bactérias do ácido láctico e seu uso como suplementos alimentares para aves domésticas |
-
2007
- 2007-09-18 KR KR1020097007854A patent/KR101460551B1/ko active IP Right Grant
- 2007-09-18 MY MYPI2013002516A patent/MY183797A/en unknown
- 2007-09-18 EP EP07842706.9A patent/EP2066339B1/en active Active
- 2007-09-18 DK DK07842706.9T patent/DK2066339T3/da active
- 2007-09-18 PL PL07842706T patent/PL2066339T3/pl unknown
- 2007-09-18 ES ES07842706.9T patent/ES2520026T3/es active Active
- 2007-09-18 US US12/441,851 patent/US8604178B2/en active Active
- 2007-09-18 EP EP12165985.8A patent/EP2517723B1/en active Active
- 2007-09-18 PT PT78427069T patent/PT2066339E/pt unknown
- 2007-09-18 EP EP14173324.6A patent/EP2857038B1/en not_active Not-in-force
- 2007-09-18 MY MYPI20091090A patent/MY188753A/en unknown
- 2007-09-18 CN CN200780037288.8A patent/CN101522210B/zh not_active Expired - Fee Related
- 2007-09-18 WO PCT/US2007/078785 patent/WO2008036675A2/en active Application Filing
-
2013
- 2013-12-09 US US14/100,957 patent/US9226957B2/en not_active Expired - Fee Related
-
2015
- 2015-12-16 US US14/971,704 patent/US10004798B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PT2066339E (pt) | 2014-10-31 |
EP2066339A4 (en) | 2010-02-03 |
MY183797A (en) | 2021-03-16 |
EP2517723A1 (en) | 2012-10-31 |
EP2857038B1 (en) | 2019-04-10 |
WO2008036675A8 (en) | 2009-08-06 |
US10004798B2 (en) | 2018-06-26 |
EP2857038A3 (en) | 2015-07-08 |
US20160114025A1 (en) | 2016-04-28 |
WO2008036675A3 (en) | 2008-12-04 |
MY188753A (en) | 2021-12-29 |
EP2066339A2 (en) | 2009-06-10 |
EP2857038A2 (en) | 2015-04-08 |
ES2520026T3 (es) | 2014-11-11 |
KR101460551B1 (ko) | 2014-11-18 |
KR20090075824A (ko) | 2009-07-09 |
PL2066339T3 (pl) | 2015-02-27 |
WO2008036675A2 (en) | 2008-03-27 |
CN101522210B (zh) | 2017-03-22 |
EP2517723B1 (en) | 2019-11-06 |
CN101522210A (zh) | 2009-09-02 |
EP2066339B1 (en) | 2014-08-13 |
US20140093534A1 (en) | 2014-04-03 |
US20110027309A1 (en) | 2011-02-03 |
US9226957B2 (en) | 2016-01-05 |
US8604178B2 (en) | 2013-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2066339T3 (da) | Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner | |
DK3097926T3 (da) | Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria | |
DK2203478T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin | |
DK2087002T3 (da) | Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat | |
DK2155188T3 (da) | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft | |
DK2081669T3 (da) | Fremgangsmåde og anordning til fremstilling af granulater | |
DK2061561T3 (da) | Sammensætninger til behandling af cancer | |
DK3178490T3 (da) | RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse | |
DK2137537T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
DK3263589T5 (da) | Peptidsekvenser og sammensætninger | |
DK3207941T3 (da) | Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater | |
DK3156069T3 (da) | Sammensætninger, fremgangsmåder, og kits til fremkaldelse af et immunrespons | |
DK2054711T3 (da) | Fremgangsmåde til fremstilling af mikroarrays | |
DK2253644T3 (da) | Sammensætninger og fremgangsmåder til fremstilling af en sammensætning | |
DK2001611T3 (da) | Fremgangsmåde og sammensætning til oprensning af jord | |
DK2135603T3 (da) | Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet | |
DK3081315T3 (da) | Fremgangsmåde og system til sortering af fødevarer | |
DK2323638T3 (da) | Sammensætninger og fremgangsmåder til behandling af osteoartritis | |
DK2470656T3 (da) | Sammensætning til hæmning af genekspression og anvendelser heraf | |
DK2700651T3 (da) | Monovalente sammensætninger til cd28-binding og fremgangsmåder til anvendelse heraf | |
BRPI0820298A2 (pt) | anticorpos anti-vegf composições e métodos | |
DK2518655T3 (da) | Anordning og fremgangsmåde til forebyggelse af hypoglykæmi | |
DK2068930T3 (da) | Sammensætninger og fremgangsmåder under anvendelse af anti-CS1-antistoffer til at behandle multiple myelomer | |
DK3263112T3 (da) | Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer | |
DK2099489T3 (da) | Sammensætninger og fremgangsmåder til behandling af en neoplasme |